Ai Feedback
Exact(14)
Subtypes can be defined by multiparameter molecular tests such as the PAM-50 [ 15] or MammaPrint/BluePrint [ 16].
When used in combination, molecular tests such as GGI are potentially important in the subclassification of grade 2 breast tumors.
Molecular tests such as GGI are promising in terms of clinical benefit, but so far the documented benefit is complementary to histopathological methods [ 32].
Several rapid molecular tests such as conventional RT-PCR (cRT-PCR) and real-time RT-PCR (rRT-PCR) have been developed for ERAV and ERBV [ 27, 31- 33].
More recently, molecular tests such as Oncotype DX® and MammaPrint® are being utilized to assess likelihood of treatment response and/or recurrence.
These preliminary data support the use of DUS as simple, rapid, and safe sampling for HPV DNA detection and genotyping by using molecular tests, such as PCR and line probe assay based on the principle of reverse hybridization.
Similar(46)
Molecular testing, such as with CMA, could significantly impact patient care by assisting the pediatric urologists and neonatologists in diagnosis.
Additional molecular testing, such as spa typing in conjunction with SCC mec typing, can then be performed to confirm the strain type.
Molecular testing, such as real-time PCR, is more sensitive, specific and less time consuming than viral culture and immunofluorescence assays.
The cost of an individual LBC test is considerably higher, but ancillary molecular testing, such as high-risk HPV testing in the case of atypical squamous cells of undetermined significance (ASC-US), can be carried out on the same sample.
Molecular testing, such as peptide-based EBV-IgA serology and EBV-DNA load testing, holds promise for early detection and down-staging NPC in Indonesia when applied on a country-wide scale.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com